Alcana

Alnylam Pharmaceuticals researchers last month published details on the company’s efforts to improve lipid nanoparticles for RNAi drug delivery.

Just days before they were scheduled to go to trial, Alnylam Pharmaceuticals and Tekmira Pharmaceuticals announced that they have hammered out a settlement to their protracted patent-infringement and technology-misappropriation lawsuits.

Tekmira Pharmaceuticals' CEO this week provided an update on the company's ongoing litigation with partner Alnylam Pharmaceuticals, confirming that a roughly one-year-old technology-misappropriation lawsuit could be resolved before the end of 2012.

Tekmira Pharmaceuticals said this week that it has secured a $3 million loan, extending its cash runway into 2013.

Tekmira Pharmaceuticals this week announced that it has filed a notice of civil claim in the Supreme Court of British Columbia alleging that “certain individuals” from AlCana Technologies wrongly took “thousands of confidential documents” containing Tekmira information and trade

Alnylam charged Tekmira with wrongly using trade secrets to bolster its own drug delivery technology-development efforts and to file a patent application on Alnylam's phase I liver cancer drug.

During a presentation to investors last week, CEO John Maraganore highlighted the company's collaborations with Massachusetts Institute of Technology and AlCana, but notably made no mention of partner Tekmira Pharmaceuticals, which sued Alnylam earlier in the year.

Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.

A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.

NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.

In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.